The Importance of Serum Omentin-1 and Visfatin Levels in Determining Acute Pancreatitis Activation

Abstract

Background Acute pancreatitis is a disease that can lead to serious mortality and morbidity. Therefore, the use of inflammatory markers is of great importance in determining the prognosis of the disease. Omentin-1 and visfatin are newly discovered adipokines associated with inflammation. In this study, we aimed to demonstrate the importance of omentin-1 and visfatin in diagnosing and activating acute pancreatitis. Methods Serum samples from 52 patients diagnosed with acute pancreatitis who presented to the Emergency Department of Çanakkale Onsekiz Mart University Health Practice and Research Hospital between July 2022 and May 2023 were analyzed for serum omentin-1 and visfatin levels, along with routine laboratory tests, during both the initial and remission periods. Disease severity was calculated using the Modified Glasgow Prognostic Score. Correlation analysis was conducted among study variables. Results The marker with the highest sensitivity and specificity in predicting active disease was found to be C-reactive protein (CRP). The sensitivity of serum omentin-1 levels in determining active disease was 84.62%, with a specificity of 73.17%. Serum visfatin levels had a sensitivity of 76.92% and a specificity of 78.05% in determining active disease. According to the Modified Glasgow Prognostic Scoring System, omentin showed the highest sensitivity (82.61%) in distinguishing mild-moderate cases from severe cases, while visfatin had the highest specificity (86.21%). Conclusion In our study, serum levels of omentin-1 and visfatin negatively correlated with disease diagnosis and severity.

Keywords

• Acute Pancreatitis
• Omentin-1
• Visfatin
• CRP

References

1. Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, Coburn NG, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016 Apr;59(2):128-40. doi: 10.1503/cjs.015015.
2. Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE. Diagnosis and Management of Acute Pancreatitis. Gastroenterology. 2024 Oct;167(4):673-688. doi: 10.1053/j.gastro.2024.02.052.
3. Goodchild G, Chouhan M, Johnson GJ. Practical guide to the management of acute pancreatitis. Frontline Gastroenterol. 2019 Jul;10(3):292-299. doi: 10.1136/flgastro-2018-101123.
4. Malheiro F, Nascimento ML, Carmo A, Borrego LM. Circulating Blood Lymphocytes and Acute Pancreatitis Severity: A Systematic Review. Cureus. 2023 Oct 23;15(10):e47532. doi: 10.7759/cureus.47532.
5. Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Front Physiol. 2020 Nov 5;11:578966. doi: 10.3389/fphys.2020.578966.
6. Kiczmer P, Szydło B, Seńkowska AP, Maziarz B, Słomka A, Kiełbik M, et al. Serum omentin-1 and chemerin concentrations in pancreatic cancer and chronic pancreatitis. Folia Med Cracov. 2018;58(2):77-87. doi: 10.24425/fmc.2018.124660.
7. Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose Tissue-Derived Omentin-1 Function and Regulation. Compr Physiol. 2017 Mar 15;7(3):765-781. doi: 10.1002/cphy.c160032.
8. Radzicka S, Pietryga M, Iciek R, Brązert J. The role of visfatin in pathogenesis of gestational diabetes (GDM). Ginekol Pol. 2018;89(9):518-521. doi: 10.5603/GP.a2018.0088.

9. Kumari B, Yadav UCS. Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements. Curr Mol Med. 2018;18(2):116-125. doi: 10.2174/1566524018666180712110347.
10. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005 Jul 31;1732(1-3):96-102. doi: 10.1016/j.bbaexp.2005.06.017.
11. Bardakçı O, Akdur G, Das M, Sıddıkoğlu D, Akdur O, Beyazit Y. Comparison of different risk stratification systems for prediction of acute pancreatitis severity in patients referred to the emergency department of a tertiary care hospital. Ulus Travma Acil Cerrahi Derg. 2022 Jul;28(7):967-973. doi: 10.14744/tjtes.2021.92847.
12. Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor JA, Yadav D, Petrov MS. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):45-55. doi: 10.1016/S2468-1253(16)30004-8.
13. Samanta J, Dhaka N, Gupta P, Kochhar R. Comparative study of the outcome between alcohol and gallstone pancreatitis in a high-volume tertiary care center. Ann Hepatobiliary Pancreat Surg. 2019 Nov;23(4):338-343. doi: 10.14701/ahbps.2019.23.4.338.
14. Hong W, Lillemoe KD, Pan S, Zimmer V, Kontopantelis E, Stock S, et al. Development and validation of a risk prediction score for severe acute pancreatitis. J Transl Med. 2019 Apr 10;17(1):146. doi: 10.1186/s12967-019-1898-8.
15. Katuchova J, Bober J, Harbulak P, Hudak A, Gajdzik T, Kalanin R, et al. Obesity as a risk factor for severe acute pancreatitis patients. Wien Klin Wochenschr. 2014 Apr;126(7-8):223-7. doi: 10.1007/s00508-013-0491-9.
16. Martínez J, Johnson CD, Sánchez-Payá J, de Madaria E, Robles-Díaz G, Pérez-Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. Pancreatology. 2006;6(3):206-9. doi: 10.1159/000092101.
17. Huang L, Chen C, Yang L, Wan R, Hu G. Neutrophil-to-lymphocyte ratio can specifically predict the severity of hypertriglyceridemia-induced acute pancreatitis compared with white blood cell. J Clin Lab Anal. 2019 Apr;33(4):e22839. doi: 10.1002/jcla.22839.
18. Wilson C, Heads A, Shenkin A, Imrie CW. C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg. 1989 Feb;76(2):177-181. doi: 10.1002/bjs.1800760224.
19. Uhl W, Büchler M, Malfertheiner P, Martini M, Beger HG. PMN-elastase in comparison with CRP, antiproteases, and LDH as indicators of necrosis in human acute pancreatitis. Pancreas. 1991 May;6(3):253-259. doi: 10.1097/00006676-199105000-00012.
20. Khanna AK, Meher S, Prakash S, Tiwary SK, Singh U, Srivastava A, Srivastava A, Dixit VK. Comparison of Ranson, Glasgow, MOSS, SIRS, BISAP, APACHE-II, CTSI Scores, IL-6, CRP, and Procalcitonin in Predicting Severity, Organ Failure, Pancreatic Necrosis, and Mortality in Acute Pancreatitis. HPB Surg. 2013;2013:367581. doi: 10.1155/2013/367581.
21. Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):479-496. doi: 10.1038/s41575-019-0158-2.
22. Zhou Q, Tao X, Xia S, Guo F, Pan C, Xiang H, Huang L. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? Front Oncol. 2020 Mar 13;10:382. doi: 10.3389/fonc.2020.00382.
23. de Jager CP, van Wijk PT, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care. 2010 Oct 5;14(5):R192. doi: 10.1186/cc9309.
24. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tarte K, Thomas R, Fauchet R, Drénou B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock. 2002 Dec;18(6):487-494. doi: 10.1097/00024382-200212000-00003.
25. Pezzilli R, Billi P, Beltrandi E, Maldini M, Mancini R, Morselli Labate AM, Gullo L. Circulating lymphocyte subsets in human acute pancreatitis. Pancreas. 1995 Jan;11(1):95-100. doi: 10.1097/00006676-199501000-00018.
26. Takeyama Y, Takas K, Ueda T, Hori Y, Goshima M, Kuroda Y. Peripheral lymphocyte reduction in severe acute pancreatitis is caused by apoptotic cell death. J Gastrointest Surg. 2000 Jul-Aug;4(4):379-387. doi: 10.1016/s1091-255x(00)80092-7.
27. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5-14.
28. Li Y, Zhao Y, Feng L, Guo R. Comparison of the prognostic values of inflammation markers in patients with acute pancreatitis: a retrospective cohort study. BMJ Open. 2017 Mar 21;7(3):e013206. doi: 10.1136/bmjopen-2016-013206.
29. Abaylı B, Gençdal G. Correlation between neutrophil/lymphocyte ratio and Ranson score in acute pancreatitis. J Clin Lab Anal. 2018;32(6):e22437. doi: 10.1002/jcla.22437.
30. Peiró C, Romacho T, Carraro R, Sánchez-Ferrer CF. Visfatin/PBEF/Nampt: A New Cardiovascular Target? Front Pharmacol. 2010 Nov 24;1:135. doi: 10.3389/fphar.2010.00135.
31. Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE. Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016 Jul;28(7):814-819. doi: 10.1097/MEG.0000000000000631.
32. Nonnecke EB, Castillo PA, Dugan AE, Almalki F, Underwood MA, De La Motte CA, Dvorak B. Human intelectin-1 (ITLN1) genetic variation and intestinal expression. Sci Rep. 2021 May 24;11(1):12889. doi: 10.1038/s41598-021-92093-z.
33. Yin J, Hou P, Wu Z, Nie Y. Decreased levels of serum omentin-1 in patients with inflammatory bowel disease. Med Sci Monit. 2015 Jan 5;21:118-122. doi: 10.12659/MSM.892729.